Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

• Status: Active, not recruiting
• Trial end date: 2023-07-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mylan Inc.; Novartis Pharmaceuticals
• Collaborators: Cystic Fibrosis Foundation; Cystic Fibrosis Foundation Therapeutics
• Treatments: Anti-Bacterial Agents; Tobramycin

Criteria

Inclusion Criteria:

• ≥ 6 years of age.

• Documented FEV1 ≥ 25% predicted in the previous year.

• Diagnosis of cystic fibrosis.

• Established diagnosis of chronic P. aeruginosa infection of the lungs defined as two or more positive P. aeruginosa cultures in the previous year as documented in the subject's medical history (this may include a history of one positive culture in the year prior to enrollment and one positive culture from the specimen collected at the baseline visit).

• Prescribed and initiated chronic treatment with FDA-approved inhaled antipseudomonal antibiotic for chronic P. aeruginosa infection (e.g. TOBI Podhaler, TOBI®, Cayston® and Bethkis®).

• Actively enrolled or willingness to enroll in PortCF registry.

• Willing and able to provide written informed consent or, parent/guardian consent and where applicable pediatric assent, for participation and use of relevant clinical data previously captured in PortCF.

• Anticipated to have good adherence to routine visits, defined as the investigator having good knowledge that the patient has been to at least 2-3 routine visits in the previous year.

Exclusion Criteria:

• Documented FEV1 < 25% predicted in the previous year.

• Current participation in an interventional clinical study with an inhaled antibiotic treatment.

• Treatment with compounded tobramycin (e.g. the use of tobramycin IV solution adapted for use by inhalation).

• Treatment with inhaled antipseudomonal antibacterial drug(s) that are not FDA approved.

• Patients undergoing an early eradication regimen for CF (first line therapy).